Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2020 Mar 13;13(1):28.
doi: 10.1186/s13048-020-00628-5.

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer

Huan Wu  1   2 , Rongrong Li  1   2 , Zhiwei Zhang  1   2 , Huiyang Jiang  1   2 , Hanlin Ma  1   2 , Cunzhong Yuan  1   2 , Chenggong Sun  1   2 , Yingwei Li  1   2 , Beihua Kong  3   4
Affiliations
Published Erratum

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer

Huan Wu et al. J Ovarian Res. .

Abstract

The original article [1] contains errors in Fig. 3C, Results and Discussion.

PubMed Disclaimer

Figures

Fig. 3
Fig. 3
Kallistatin (KAL) inhibited the proliferation of ovarian cancer cells in vitro and in vivo. (a) The effect of kallistatin on ovarian cancer cell proliferation as measured by MTT assays; A2780 and UWB1.289 cells were transfected stably with PCMV-NC and PCMV-KAL. A2780 and OVCAR3 cells were transfected transiently with kallistatin siRNA. (b) Colony formation assays were used to measure the effect of kallistatin on A2780, UWB1.289 and OVCAR3 cell growth. (c) Cell cycle analysis of A2780 and OVCAR3 cells. (d, e) UWB1.289 cells stably transfected with PCMV-NC and PCMV-KAL were injected subcutaneously into nude female mice. The tumour weights in the PCMV-KAL group were significantly decreased compared with those in the control group. *p < 0.05, **p < 0.01, ***p < 0.001
See this image and copyright information in PMC

Erratum for

References

    1. Wu H, Li R, Zhang Z, et al. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer. J Ovarian Res. 2019;12:125. doi: 10.1186/s13048-019-0601-6. - DOI - PMC - PubMed

Publication types

LinkOut - more resources